Here are three highlights from the first quarter:
1. Data from Ironwood’s investigational gastric retentive bile acid sequestrant demonstrated improvements in relief of heartburn and other symptoms.
2. Ironwood reported continued activity with a Phase IIa clinical study evaluating the ability of guanylate cyclase-C agonist to provide diabetic gastroparesis symptom relief.
3. Dosing began in a Phase I clinical study of he first clinical compound in a broad library of sGC stimulators for the potential treatment of cardiovascular disease.
More articles on GI/endoscopy:
UMass Memorial Medical Group adds Dr. Kerri Gosselin — 3 quick facts
Tissue-engineered small intestine successful — Is a new short bowel syndrome treatment next? 3 things to know
Cahaba GBA to cover EndoGastric Solutions’ TIF procedure: 4 important takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
